SEC Filings

Form 10-K
XBIOTECH INC. filed this Form 10-K on 03/14/2019
Document Outline
Entire Document (2300.8 KB)
Subdocument 1 - 10-K - FORM 10-K
Page 1 - UNITED STATES
Page 2 - Documents incorporated by reference:
Page 3 - CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Page 4 - N/A
Page 5 - PART I
Page 6 - N/A
Page 7 - N/A
Page 8 - A Background on Therapeutic Antibodies
Page 9 - Industry Context
Page 10 - Our Strategy
Page 11 - Competition
Page 12 - Phase I Pancreatic Cancer Combination Study
Page 13 - Intellectual Property
Page 14 - H. Cachexia Treatment. This patent family relates to the administration of anti-IL-1 antibodies to t
Page 15 - Q. Treatment of Atopic Dermatitis. This patent family relates to the use of antibodies (Abs) which s
Page 16 - Raising additional capital may cause dilution to our existing shareholders, restrict our operations
Page 17 - Risks Related to Our Business
Page 18 - Our future success is dependent on the regulatory approval and commercialization of our lead product
Page 19 - New laws or regulations may be promulgated or modified in the United States, in Europe, or other jur
Page 20 - Because the results of earlier clinical trials are not necessarily predictive of future results, pro
Page 21 - The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengt
Page 22 - Our lead product candidate or our other product candidates may cause undesirable side effects or hav
Page 23 - Even if our lead product candidate or our other product candidates receive regulatory approval, they
Page 24 - Failure to obtain regulatory approval in foreign jurisdictions would prevent our lead product candid
Page 25 - Even if we are able to commercialize our lead product candidate or our other product candidates, the
Page 26 - Our lead product candidate and our other product candidates, if approved, may not achieve adequate m
Page 27 - Even an effective drug candidate might not be commercially successful.
Page 28 - Product liability lawsuits against us could cause us to incur substantial liabilities and to limit c
Page 29 - We will need to expand our operations and grow the size of our organization in the future, and we ma
Page 30 - If we fail to comply with environmental, health and safety laws and regulations, we could become sub
Page 31 - Intellectual property rights do not necessarily address all potential threats to any competitive adv
Page 32 - We may need to license intellectual property from third parties, and such licenses may not be availa
Page 33 - Risks Related to Owning Shares of Our Common Stock
Page 34 - Insiders continue to have substantial control over our company since our initial public offering in
Page 35 - We may be a passive foreign investment company for US tax purposes which may negatively affect US in
Page 36 - If we fail to maintain an effective system of internal control over financial reporting, we may not
Page 37 - N/A
Page 38 - PART II
Page 39 - Use of Proceeds from IPO
Page 40 - RESULTS OF OPERATIONS
Page 41 - General and Administrative Expenses
Page 42 - Results of Operations
Page 43 - N/A
Page 44 - Other Income
Page 45 - Contractual Obligations and Commitments
Page 46 - Index to Financial Statements
Page 47 - Report of Independent Registered Public Accounting Firm
Page 48 - XBiotech Inc.
Page 49 - XBiotech Inc.
Page 50 - XBiotech Inc.
Page 51 - XBiotech Inc.
Page 52 - XBiotech Inc.
Page 53 - XBiotech Inc.
Page 54 - Research and Development Costs
Page 55 - Cash and Cash Equivalents
Page 56 - Property and Equipment
Page 57 - Net Loss per Share
Page 58 - 4. Accrued Expenses
Page 59 - 7. Net Loss Per Share
Page 60 - 8. Income Taxes
Page 61 - 9. Commitments and Contingencies
Page 62 - 10. Selected Quarterly Financial Data (Unaudited)
Page 63 - Management's Evaluation of our Disclosure Controls and Procedures
Page 64 - PART III
Page 65 - N/A
Page 66 - SIGNATURES
Page 67 - EXHIBIT INDEX
Page 68 - N/A
Subdocument 2 - EX-21.1 - EXHIBIT 21.1
Page 1 - N/A
Subdocument 3 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A
Subdocument 4 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 5 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 6 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
Subdocument 7 - EX-32.2 - EXHIBIT 32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer